167 related articles for article (PubMed ID: 24928564)
1. Utility and importance of animal data in drug product labels.
Baldrick P
Regul Toxicol Pharmacol; 2014 Aug; 69(3):546-57. PubMed ID: 24928564
[TBL] [Abstract][Full Text] [Related]
2. Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development.
Nieminen O; Kurki P; Nordström K
Eur J Pharm Biopharm; 2005 Aug; 60(3):319-26. PubMed ID: 15996576
[TBL] [Abstract][Full Text] [Related]
3. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels.
Wang B; Canestaro WJ; Choudhry NK
JAMA Intern Med; 2014 Dec; 174(12):1938-44. PubMed ID: 25317785
[TBL] [Abstract][Full Text] [Related]
4. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.
Citrome L; Nasrallah HA
Expert Opin Pharmacother; 2012 Aug; 13(11):1599-613. PubMed ID: 22017361
[TBL] [Abstract][Full Text] [Related]
5. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
[TBL] [Abstract][Full Text] [Related]
7. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
Watson KT; Barash PG
Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
[TBL] [Abstract][Full Text] [Related]
8. Assessment of geriatric information on the drug label for commonly prescribed drugs in older people.
Steinmetz KL; Coley KC; Pollock BG
J Am Geriatr Soc; 2005 May; 53(5):891-4. PubMed ID: 15877571
[TBL] [Abstract][Full Text] [Related]
9. Applications of pharmacogenomics in regulatory science: a product life cycle review.
Tan-Koi WC; Leow PC; Teo YY
Pharmacogenomics J; 2018 May; 18(3):359-366. PubMed ID: 29205206
[TBL] [Abstract][Full Text] [Related]
10. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
11. A cross-national comparison of 17 countries' insulin glargine drug labels.
Polinski JM; Kesselheim AS; Seeger JD; Connolly JG; Choudhry NK; Shrank WH
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):159-65. PubMed ID: 25250724
[TBL] [Abstract][Full Text] [Related]
12. Descriptive analysis of primary package labels from commercially available prescription solid oral dosage form drugs.
Chermak TE; Lambert BL
J Am Pharm Assoc (2003); 2009; 49(3):399-406. PubMed ID: 19443320
[TBL] [Abstract][Full Text] [Related]
13. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
[TBL] [Abstract][Full Text] [Related]
14. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Saito M; Hirata-Koizumi M; Urano T; Miyake S; Hasegawa R
J Clin Pharm Ther; 2005 Feb; 30(1):21-37. PubMed ID: 15659001
[TBL] [Abstract][Full Text] [Related]
15. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
16. Prescription drug products; revocation of patient package insert requirements--Food and Drug Administration. Final rule.
Fed Regist; 1982 Sep; 47(173):39147-55. PubMed ID: 10258154
[TBL] [Abstract][Full Text] [Related]
17. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
[TBL] [Abstract][Full Text] [Related]
18. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
19. The product label: how pharmacokinetics and pharmacodynamics reach the prescriber.
Marroum PJ; Gobburu J
Clin Pharmacokinet; 2002; 41(3):161-9. PubMed ID: 11929317
[TBL] [Abstract][Full Text] [Related]
20. How should ethnicity-related information be included on drug labels? Considerations based on comparison of multiregional clinical trial data on the label between Japan and the United States.
Tanaka A; Asano K; Uyama Y
Clin Pharmacol Ther; 2015 Nov; 98(5):480-2. PubMed ID: 26250551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
